News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
Incyte Corporation Arthritis Drug Shows Promise; Positive Phase 2 Data Triggers $30 Million Milestone from Eli Lilly and Company
May 6, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Biotechnology firm Incyte Corp said data from a mid-stage trial of its experimental rheumatoid arthritis treatment showed the drug was safe and effective.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Clinical research
Phase II
Eli Lilly and Company
Incyte
MORE ON THIS TOPIC
Drug Pricing
BMS, Pfizer Join DTC Trend, Offering Eliquis to Patients for 40% Below List Price
July 17, 2025
·
2 min read
·
Nick Paul Taylor
Layoffs
Sarepta Up 18% After Business Overhaul as Analysts Cautiously Optimistic
July 17, 2025
·
1 min read
·
Heather McKenzie
Tariffs
Novartis ‘Moving as Fast as Possible’ to Fully Manufacture Key Drugs in US as Tariffs Near
July 17, 2025
·
2 min read
·
Tristan Manalac
Layoffs
Sarepta Tags DMD Gene Therapy Elevidys With Black Box Warning, Axes 500 Staff
July 16, 2025
·
2 min read
·
Heather McKenzie
